Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
Follow SNOA
Sonoma Pharmaceuticals, Inc. (SNOA) EV/Sales
As of 16 October 2026, Sonoma Pharmaceuticals, Inc. (SNOA) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −0.2× (April 2025) to 2.7× (December 2016); the current reading is higher than 11% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.1× | — |
| FY2025 | −0.2× | — |
| FY2024 | −0.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.3× | (48.58%) |
| FY2021 | 0.7× | 152.12% |
| FY2020 | 0.3× | 17.71% |
| FY2019 | 0.2× | (48.37%) |
| FY2018 | 0.4× | (57.41%) |
| FY2017 | 1.0× | 16.33% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.1× | (69.08%) |
| Dec 2025 | 0.2× | 4.52% |
| Sep 2025 | 0.2× | 159.69% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. | 0.0× |
| GELS Gelteq Limited compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| YCBD cbdMD, Inc. compare | 0.2× |
| BFRI Biofrontera Inc. compare | 0.2× |
| INM InMed Pharmaceuticals Inc. compare | 0.6× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)